Prot #BGB-3111-304: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Project: Research project

Project Details

StatusActive
Effective start/end date2/5/19 → 2/5/27

Funding

  • PRA Health Sciences ((OE) Prot #BGB-3111-304 // (OE) Prot #BGB-3111-304)
  • BeiGene Ltd. ((OE) Prot #BGB-3111-304 // (OE) Prot #BGB-3111-304)